Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The estrogen-ECM-integrin- cytoskeleton axis in pelvic organ prolapse: a mechanobiological framework linking matrix remodeling to repair failure.

Created on 17 Nov 2026

Authors

Xiaoyue Yang, Lan Chen, Xiaohan Wang, Minjiao Zhu, Zheng Chen, Xuan Zheng, Qin Lin

Published in

Frontiers in bioengineering and biotechnology. Volume 14. Pages 1949172. Epub Nov 02, 2026.

Abstract

Pelvic organ prolapse (POP) is a common disorder of pelvic support, but its estimated prevalence depends strongly on ascertainment. A 2024 meta-analysis reported a pooled prevalence of 30.9%, increasing to 41.8% in examination-based studies. Altered collagen turnover and estrogen-responsive tissue remodeling are important features of POP, yet they do not fully explain how extracellular-matrix (ECM) abnormalities may become persistent defects in cellular force transmission and repair. This narrative Review develops an evidence-graded estrogen-ECM-integrin-cytoskeleton axis, organized around ECM mechanics and fibroblast mechanosensing. We distinguish ERα-, ERβ- and GPER-mediated signaling; indirect hormonal effects on the matrix presented to integrins; and the more limited evidence for direct hormonal control of integrin signaling in human POP. We examine LOX/LOXL-dependent matrix maturation while separating expression, catalytic activity and mature cross-link measurements. The integrin-talin-vinculin molecular clutch provides a candidate connection between abnormal matrix resistance, FAK/Src-RhoA/ROCK signaling, cytoskeletal function and YAP/TAZ-dependent transcription. However, POP-associated mechanics vary with tissue compartment, measurement scale and disease state. Reduced counter-resistance and clutch slippage therefore represent a testable scenario, not a universal disease sequence. We identify experiments that could distinguish matrix-mediated effects from intrinsic fibroblast dysfunction and connect these questions to biomaterial design, controlled loading and local pathway modulation. Clinical estrogen therapy and experimental mechanopharmacology must remain distinct: improved local tissue quality does not establish prevention of prolapse recurrence, and no YAP/TAZ-targeted drug is approved for POP.

PMID:
43041299
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement